dine amp learn roundtable ckd what to expect
play

Dine & Learn Roundtable CKD What to Expect Dr. Caroline Stigant April 30, 2019 4/25/2019 CHRONIC KIDNEY DISEASE - DEFINITION 1. Persistently* abnormal kidney function (ie. GFR < 60 mL/min) due to intrinsic disease of the kidney(s) or

0 downloads 3 Views 513 KB Size Report
  1. Dine & Learn Roundtable CKD – What to Expect Dr. Caroline Stigant April 30, 2019

  2. 4/25/2019 CHRONIC KIDNEY DISEASE - DEFINITION 1. Persistently* abnormal kidney function (ie. GFR < 60 mL/min) due to intrinsic disease of the kidney(s) or 2. Normal function (ie. GFR > 60), but persistent* structural or functional abnormality of the kidneys, with either - pathological abnormalities - markers of kidney damage (ie. proteinuria, hematuria) - kidney transplant examples: early PCKD, low-grade nephritis, well functioning kidney transplant * Persistent = >3 months ‘CGA’ of Kidney Disease Screening Cause, GFR, and Albuminuria all required for assessing risk of complications and future outcomes Green: low risk; Yellow: moderately increased risk; Orange: high risk; Red: very high risk 1

  3. 4/25/2019 COMMON CAUSES OF THE SYNDROME OF CKD • Hypertension • Diabetes 99% of the diagnoses, - most often normal urinalysis • Ischemic / vascular - usually low-grade albuminuria (except DM) • Glomerular disease • PCKD • Drug-Induced • Pyelonephritis • Reflux GFR DECLINES WITH AGE (Average – 1 to 2 mL/min/year) 2

  4. 4/25/2019 NEPHRONS ARE LOST WITH AGING, PROPORTIONAL TO GFR DECLINE The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging Denic A et al. JASN 2017;28 Normal kidney 3

  5. 4/25/2019 Nephrosclerosis NATURAL HISTORY OF CKD • Results vary between studies and according to diagnosis, in general: • Non-proteinuric disease / general population: -1 mL/min GFR per year • Diabetes (untreated): -5-10 mL/min/yr • Diabetes (treated): 1-5 mL/min/yr\ • Non-diabetic proteinuria: up to 10+ mL/min/yr • Often a different syndrome • Nephritic (hematuria, proteinuria, edema, hypertension) • Nephrotic (albuminuria 3+ grams daily, hypoalbuminemia, edema, hypercholesterolemia) • ‘RPGN’ – Rapidly progressive glomerulonephritis – active urine sediment with marked loss of kidney function over weeks to months 4

  6. 4/25/2019 WHAT TO DO IF ABNORMAL RESULT • For patients with a new finding of an eGFR < 60 mL/min or urine abnormality, determine stability of patient’s kidney status by: • Repeating within week(s), • and then in 3-6 months • ALWAYS GET URINALYSIS AND URINE ACR • Is this ‘just’ a hemodynamic change or is this a different renal syndrome • Except if severely abnormal (GFR < 30) • Assess, repeat sooner, &/or involve nephrologist • ONE MEASUREMENT IS NOT ENOUGH PLEASE ALWAYS ALWAYS ALWAYS CONSIDER REVERSIBLE FACTORS • Intercurrent illness • Volume depletion • Medications • NSAIDs, aminoglycosides, IV contrast dye, diuretics • Obstruction • Remember: small fluctuations are common and not indicative of progression 5

  7. 4/25/2019 Identify patients in your practice at high risk for Chronic Kidney Disease - Patients with hypertension - Patients with heart failure - Patients with diabetes mellitus - Patients with unexplained anemia - Patients with atherosclerotic coronary, - Patients with a family history of end stage renal disease cerebral or peripheral vascular disease - High risk ethnicity eGFR 30-60 eGFR >60 eGFR <30 Consider reversible factors: Individualized follow up -Medication - Volume depletion and treatment -Intercurrent illness - Obstruction CKD is diagnosed in this group only if other renal abnormalities are present Repeat tests (usually in 2 - 4 weeks) (i.e. proteinuria, hematuria, anatomical) eGFR <30 eGFR 30-60 Nephrology referral Follow eGFR at 3 months then serially recommended Assess for persistent significant proteinuria Implement risk reduction eGFR < 30 Stable eGFR 30-60 or progressive decline in eGFR and or persistent significant proteinuria no significant proteinuria or inability to attain treatment targets Impact of Lifestyle Therapies on Blood Pressure in Hypertensive Adults Intervention Intervention SBP/DBP -1800 mg/day* sodium Reduce foods with -5.1 / -2.7 added sodium Hypertensive Weight loss -1.1 / -0.9 -1 kg -3.9 / -2.4 Alcohol intake -3.6 drinks/day Aerobic exercise -4.9 / -3.7 120-150 min/week DASH diet Dietary patterns Hypertensive -11.4 / -5.5 Normotensive -3.6 / -1.8 Applying the 2005 Canadian Hypertension Education Program recommendations: 3. Lifestyle modifications to prevent and treat * 2,300 mg sodium = 1 level teaspoon of table salt hypertension Padwal R. et al. CMAJ ・ SEPT. 27, 2005; 173 (7) 749-751 6

  8. 4/25/2019 KIDNEY DISEASE MANAGEMENT: NON-SPECIFIC TREATMENTS • BP control • Target < 140/90 non-diabetic CKD, < 130/80 diabetic CKD • ACE inhibitor &/or Angiotensin receptor blocker usual 1 st line agent, especially if albuminuria present • Glycemic control if diabetic • Dietary protein restriction • Dietary sodium restriction • General lifestyle: weight reduction, exercise, smoking cessation, vaccinations (influenza, pneumovax, +/- Hepatitis B) • Other: • Acidosis correction (NaHCO 3 ) • ? Statin therapy • ? Uric acid lowering therapy • INFORM PATIENTS of their GFR & activate them with self-care (ie. BP monitoring, diet changes, tracking lab data) 7

Recommend Documents


engaging arizona tribal communities in environmental
Engaging Arizona Tribal Communities in

Engaging Arizona Tribal Communities in Environmental Public Health Work

september 2020 welcome to roundtable
September 2020 Welcome to Roundtable!

September 2020 Welcome to Roundtable! Learn Share Engage 1 Invocation

tonight we dine in shell tonight we dine in shell
Tonight we dine in shell Tonight we

Lecture 3 Lecture 3 Tonight we dine in shell Tonight we dine in shell

wellbeing in the tech
Wellbeing in the Tech Industry Dr

Managing for Mental Wellbeing in the Tech Industry Dr Michelle OSullivan

susy landscape and the higgs
SUSY, Landscape and the Higgs Michael

SUSY, Landscape and the Higgs Michael Dine Department of Physics University

discrete r symmetries and low energy supersymmetry
Discrete R Symmetries and Low Energy

Discrete R Symmetries and Low Energy Supersymmetry UC Davis, 2011 Michael

sardi ne
SARDI NE RE BUI L DI NG PL AN 1

Ag e nda I te m G.1.b Supple me nta l Pub lic Pre se nta tio n 1 June

twin valley roundtable
Twin Valley Roundtable October 8 th ,

Twin Valley Roundtable October 8 th , 2020 Welcome to Octobers Roundtable

twin valley roundtable
Twin Valley Roundtable September10,

Twin Valley Roundtable September10, 2020 Welcome to September Roundtable

learn blackboard learn
Learn Blackboard Learn Learn with

Learn Blackboard Learn Learn with others Learn in your own time, pace, space

management of management of hypertension hypertension
Management of Management of

Management of Management of Hypertension Hypertension M Misra MD MRCP (UK)

glycocalyx loss
Glycocalyx Loss Podocyte and Kidney

Glycocalyx Loss Podocyte and Kidney Injury Induces Albuminuria Nat Rev

submit
SUBMIT Cas ase P e Presen entat

SUBMIT Cas ase P e Presen entat ation COVID-19 Kurt DeVine, MD and

make it count
Make it count Technical considerations

Make it count Technical considerations and initial findings for accurate

systemic lupus erythematosus presentjng as acute adrenal
Systemic Lupus Erythematosus Presentjng

[Downloaded free from http://www.amhsr.org] Case Report Systemic Lupus

a 12 year old with liver disease and pulmonary
A 12 Year Old with Liver Disease and

A 12 Year Old with Liver Disease and Pulmonary Hypertension Russel Hirsch,

chronic kidney disease a team based quality improvement
Chronic Kidney Disease A Team-Based

Chronic Kidney Disease A Team-Based Quality Improvement Project Implementing

decrements in gfr largely correlates to the
decrements in GFR largely correlates

is a physiological property determine function of all single nephrons taken

optimizing renal function pre and post resection of
Optimizing Renal Function Pre- and

Optimizing Renal Function Pre- and Post-Resection of Kidney Cancer : Important

glomerulonephritis notes
Glomerulonephritis notes ! Neil Turner

24/10/2013' Glomerulonephritis 1 Neil Turner Glomerulonephritis

use of lipoprotein a in clinical practice a biomarker
Use of Lipoprotein(a) in Clinical

Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come.

hypertension secondary to neonatal hyperleptinaemia
hypertension secondary to neonatal

Note: for non-commercial purposes only KCL Division of Womens Health